NASDAQ:DYN - Dyne Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.25
  • Forecasted Upside: 67.40 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$20.46
▼ -0.48 (-2.29%)
1 month | 3 months | 12 months
Get New Dyne Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DYN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DYN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.25
▲ +67.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $34.25, with a high forecast of $47.00 and a low forecast of $27.00. The average price target represents a 67.40% upside from the last price of $20.46.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Dyne Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021JonestradingInitiated CoverageBuyLow
i
10/12/2020JPMorgan Chase & Co.Initiated CoverageOverweight$27.00N/A
i
10/12/2020Stifel NicolausInitiated CoverageBuy$29.00N/A
i
10/12/2020Piper SandlerInitiated CoverageOverweight$34.00N/A
i
10/12/2020Jefferies Financial GroupInitiated CoverageBuy$47.00N/A
i
4/10/2018GuggenheimReiterated RatingBuyLow
i
3/6/2018SunTrust BanksReiterated RatingHold$14.00Low
i
Rating by Ali Agha at SunTrust Banks, Inc.
1/22/2018SunTrust BanksSet Price TargetHold$13.00Low
i
Rating by Ali Agha at SunTrust Banks, Inc.
11/2/2017Royal Bank of CanadaReiterated RatingHold$12.10N/A
i
10/31/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$13.00N/A
i
10/30/2017CitigroupSet Price TargetBuy$12.00N/A
i
Rating by Praful Mehta at Citigroup Inc.
10/27/2017SunTrust BanksDowngradeBuy ➝ HoldN/A
i
10/26/2017Morgan StanleySet Price TargetBuy$15.00N/A
i
Rating by Devin McDermott at Morgan Stanley
10/24/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$11.00N/A
i
10/17/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellN/A
i
10/13/2017SunTrust BanksReiterated RatingBuyN/A
i
10/10/2017Royal Bank of CanadaReiterated RatingHold$8.00N/A
i
9/4/2017Royal Bank of CanadaReiterated RatingHold$8.00High
i
8/21/2017GuggenheimReiterated RatingBuy$14.00 ➝ $18.00High
i
8/7/2017Deutsche Bank AktiengesellschaftLower Price TargetHold$11.00 ➝ $10.00Low
i
Rating by Abe Azar at Deutsche Bank Aktiengesellschaft
7/25/2017BarclaysReiterated RatingBuy$13.00Low
i
4/26/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$6.00 ➝ $7.00High
i
Rating by Abe Azar at Deutsche Bank Aktiengesellschaft
3/15/2017Royal Bank of CanadaReiterated RatingHold$8.00High
i
2/21/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$7.01 ➝ $10.00N/A
i
2/9/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$8.00 ➝ $6.00N/A
i
Rating by Abe Azar at Deutsche Bank Aktiengesellschaft
1/20/2017BarclaysBoost Price TargetBuy$13.00 ➝ $14.00N/A
i
1/18/2017UBS GroupDowngradeNeutral ➝ Sell$8.00 ➝ $7.00N/A
i
Rating by julien dumoulin smith at UBS Group AG
1/4/2017Royal Bank of CanadaReiterated RatingHold$9.00N/A
i
12/20/2016Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$7.01 ➝ $8.60N/A
i
Rating by abe azar at Deutsche Bank Aktiengesellschaft
10/20/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$22.00 ➝ $15.00N/A
i
Rating by Shelby Tucker at Royal Bank of Canada
9/15/2016UBS GroupLower Price TargetNeutral$22.00 ➝ $13.50N/A
i
Rating by Julien Dumoulin Smith at UBS Group AG
9/13/2016Wolfe ResearchDowngradeOutperform ➝ Market PerformN/A
i
8/25/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$35.00N/A
i
Rating by abe azar at Deutsche Bank Aktiengesellschaft
8/24/2016SunTrust BanksLower Price TargetBuy$20.00 ➝ $19.00N/A
i
8/5/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$24.00 ➝ $23.00N/A
i
Rating by Jonathan Arnold at Deutsche Bank Aktiengesellschaft
6/29/2016SunTrust BanksUpgradeNeutral ➝ Buy$18.00 ➝ $20.00N/A
i
6/29/2016CitigroupUpgradeNeutral ➝ Buy$21.00 ➝ $19.00N/A
i
Rating by Praful Mehta at Citigroup Inc.
6/17/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Shelby Tucker at Royal Bank of Canada
6/17/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$21.00N/A
i
Rating by Jonathan Arnold at Deutsche Bank Aktiengesellschaft
6/16/2016UBS GroupReiterated RatingHold$22.00N/A
i
Rating by Julien Dumoulin Smith at UBS Group AG
(Data available from 6/16/2016 forward)
Dyne Therapeutics logo
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $20.46
$20.20
$21.29

50 Day Range

MA: $18.35
$16.44
$20.94

52 Week Range

Now: $20.46
$13.50
$32.31

Volume

241,836 shs

Average Volume

346,822 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dyne Therapeutics?

The following sell-side analysts have issued research reports on Dyne Therapeutics in the last twelve months: Jefferies Financial Group Inc., Jonestrading, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for DYN.

What is the current price target for Dyne Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Dyne Therapeutics in the last year. Their average twelve-month price target is $34.25, suggesting a possible upside of 67.4%. Jefferies Financial Group Inc. has the highest price target set, predicting DYN will reach $47.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $27.00 for Dyne Therapeutics in the next year.
View the latest price targets for DYN.

What is the current consensus analyst rating for Dyne Therapeutics?

Dyne Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DYN will outperform the market and that investors should add to their positions of Dyne Therapeutics.
View the latest ratings for DYN.

What other companies compete with Dyne Therapeutics?

How do I contact Dyne Therapeutics' investor relations team?

The company's listed phone number is 781 786 8230 and its investor relations email address is [email protected] The official website for Dyne Therapeutics is www.dyne-tx.com.